Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism by Moyes, V. J. et al.
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2010, Article ID 906163, 4 pages
doi:10.1155/2010/906163
Clinical Study
ClinicalUse of Cinacalcetin MEN1 Hyperparathyroidism
V .J .M o y e s ,J .P .M o n s o n ,S .L .Ch e w ,an dS .A .Ak k e r
Department of Endocrinology, St. Bartholomew’s Hospital, London EC1A 7BE, UK
Correspondence should be addressed to S. A. Akker, s.a.akker@qmul.ac.uk
Received 29 December 2009; Accepted 8 March 2010
Academic Editor: Aaron I. Vinik
Copyright © 2010 V. J. Moyes et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Management of multiple-endocrine neoplasia type 1- (MEN1-) associated hyperparathyroidism is associated with
high recurrence rates and high surgical morbidity due to multiple neck explorations. Cinacalcet, a calcimimetic agent licensed
for the treatment of secondary hyperparathyroidism and parathyroid carcinoma, may provide a medical alternative for the
managementofthesecomplexpatients.Methods.Aprospectiveauditwasperformedofeightpatients;threemalesandﬁvefemales,
aged 20–38 at diagnosis. Two patients commenced cinacalcet as primary treatment and six had previous surgery. Six patients had
complications of hyperparathyroidism: renal calculi, renal dysfunction, and reduced bone mineral density. All were commenced
on cinacalcet 30mg bd for MEN1 associated hyperparathyroidism; doses were subsequently reduced to 30mg od in four patients.
Results. Signiﬁcant reductions were observed in serum calcium and PTH measurements. Serum calcium reduced by a median of
0.35mmol/L (P = .012 Wilcoxon Signed Rank). Serum PTH levels decreased by a median of 5.05pmol/L (P = .012). There was no
change in urine calcium. Duration ranged from 10–35 months with maintenance of control. Cinacalcet was well tolerated by six
patients; one experienced nausea and one experienced diarrhoea. Conclusion. Cinacalcet is an eﬀective and well-tolerated medical
treatment for the management of complex primary hyperparathyroidism.
1.Introduction
Primary hyperparathyroidism (PHPT) in Multiple Endo-
crine Neoplasia Type I (MEN1) has a penetrance rate of
nearly 100% by the age of 50 years [1]. The underlying
pathology in MEN1 PHPT diﬀers from sporadic disease;
parathyroid hyperplasia is present rather than a monoclonal
adenoma. Diﬀe r e n c e si nt h en a t u r a lh i s t o r ya r ee v i d e n t ;
patients present at a younger age (20–25 years) with early
onset of complications for example, aﬀected women have a
reduced bone mineral density (BMD) by the age of 35 years
[2]. Eﬀective management of MEN1 PHPT is advisable to
reduce complication rates; a signiﬁcant reduction in BMD
has been observed in MEN1 patients with uncontrolled
PHPTcomparedtothose withcontrolledPHPT[2].Surgical
cure of MEN1 PHPT is diﬃcult to achieve; multiple gland
hyperplasia, involvement of more than 4 glands and ectopic
locations such as the mediastinum dictate the need for thor-
ough preoperative localisation. There remains controversy
over the optimal surgical intervention; total parathyroidec-
tomy necessitates the use of long-term activated vitamin
D and the potential complication of hypercalciuria. Whilst
subtotal parathyroidectomy avoids this, further hyperplasia
is likely to occur in residual parathyroid tissue; recurrence
rates of 50% were reported at 8–12 years post successful
subtotal parathyroidectomy [3]. Multiple operations are
often required with a consequent increase in surgical mor-
bidity.
Cinacalcet is a potential medical alternative; by alloster-
ically modulating the calcium sensing receptor on the PTH
cell, it increases sensitivity to extracellular calcium and
down-regulates PTH secretion. It is licensed for the man-
agement of secondary hyperparathyroidism and parathyroid
carcinoma [4, 5]. In primary hyperparathyroidism, reduc-
tions in serum calcium and to a lesser extent serum PTH
levels have been demonstrated [6, 7], but the likelihood of
surgical cure in sporadic disease usually avoids the need for
additional medical intervention.
2. Patients andMethods
We reviewed the clinical data of nine patients treated
with cinacalcet for MEN-1 PHPT with institutional board2 International Journal of Endocrinology
Table 1: Summary of clinical details, demographics and biochemical data for the cohort studied. This table summarises the details regarding
the diagnosis of MEN1, parathyroid disease, and biochemical data pre- and post commencement of cinacalcet. A signiﬁcant reduction in
serum corrected calcium and serum PTH was determined. Bracketed () results indicate PTH levels taken 4 hours post dose.
Pt Age/ M/F Diagnoses
Prev PTH
surgery
(No)
Number
Glands
removed
Complications Serum corr-
Calciummmol/L
Serum
PTHpmol/L
Low
BMD Renal Calculi Low
GFR Pre Post Pre Post
1 35
F
PTH, PRL,
NF Islet cell 0 n/a N N N 2.62 2.26 35.8 29.4 (41.7)
2 40
M PTH, PRL 1 3 N Y N 2.64 2.54 17.6 12.4
3 58
M
PTH,
Gastrinoma 2 4 Y N Y 2.81 2.13 14.1 6.8 (12.8)
4 52
M
PTH,
NF Islet cell 1 3 Y N N 2.76 2.21 4.8 2.8(3.1)
5 53
F
PTH, NFPA,
Gastrinoma 4 2 Y Y Y 2.74 2.51 9.8 7.7(3.8)
6 26
F
PTH,
NF Islet cell 1 3 N N N 2.84 2.44 7.3 2.4(2.4)
7 46
F
PTH,
Gastrinoma 0 n/a Y Y Y 2.91 2.30 36.5 11.7
8 38
F
PTH, PRL,
Gastrinoma 1 2 Y Y N 2.75 2.40 21.5 18.6
Key: M: Male; F: female; PTH: Hyperparathyroidism; PRL: prolactinoma; NF Islet Cell: Non functioning Islet Cell tumour; BMD: Bone Mineral Density; n/a
not applicable; No: number; GFR:Glomerular Filtration Rate.
approval. The cohort consisted of three males, ﬁve females,
aged 20–38 years at diagnosis (Table 1). All had clinical
MEN1 with positive menin mutation. All patients had
hypercalcaemia and elevated serum PTH levels conﬁrmed
at diagnosis. Six had previous noncurative surgical interven-
tion; two had multiple prior neck explorations. Two patients
were unable to undergo surgery; one due to severe learning
diﬃculties and the second due to an anxiety disorder, and
cinacalcet was commenced as primary treatment.
Pretreatment serum calcium levels ranged 2.62–2.91
mmol/L, median 2.76mmol/L (reference range 2.15–
2.65mmol/L), and PTH levels ranged 4.8–36.5pmol/L,
median 15.9pmol/L (reference range 1.3–6.8pmol/L). All
patients deﬁcient in 25-hydroxy vitamin D were commenced
on supplements and achieved levels within the laboratory
referencerangepriortocommencementofcinacalcet.Sixout
of eight patients exhibited complications of PHPT: reduced
BMD in ﬁve patients, (T score of less than −2.5), renal
calculiinfourpatients,andrenaldysfunctioninfourpatients
(>25% reduction in creatinine clearance). Two patients had
nocomplicationsofhyperparathyroidismbutwereunderthe
age of 50; all patients therefore fulﬁlled criteria for treatment
as determined by the Consensus on the management of
asymptomatic primary hyperparathyroidism 2002 [8].
Cinacalcet was generously provided by Amgen on a
compassionate-use basis to the hospital for no charge. After
a product license was obtained in the UK for use in renal
failure-related hyperparathyroidism, it was prescribed on an
oﬀlabelbasisat30mgtwicedaily.Thedosewassubsequently
reduced in four patients: two due to clinical response and
two due to side eﬀects. Due to the pharmacokinetics of
cinacalcet, all serum calcium and PTH measurements were
takenpredoseaccordingtoadeﬁnedprotocol.Assteadystate
druglevelsareachievedafter7days,resultsoftheﬁrstclinical
assessment (three months postcommencement) were used
for comparison.
3.StatisticalAnalysis
Statistical signiﬁcance was accepted at a P value <. 05. All
variables studied were normally distributed. The nonpara-
metric Wilcoxon Signed Ranks Test was performed for the
comparison of the variables between the studied groups
because of the small sample size.
Analysis was performed using SPSS (version 11.01; Spss,
Inc., Chicago, IL) for W indows XP (Microsoft Corp).
4. Results
All patients achieved normocalcaemia on cinacalcet with
a median posttreatment serum corrected calcium of
2.35mmol/L, range of 2.13–2.54mmol/L. Serum cal-
cium reduced by a median of 0.68mmol/L, range of
0.10–0.68mmol/L, and was statistically signiﬁcant (P =
.012) (Figure 1(a)). Serum PTH reduced by median of
5.05pmol/L, range of 0.7–24.8pmol/L, (P = .012) (Figure
1(b)). Analyses were repeated following removal of a
potential outlier (patient number 8) to conﬁrm statistical
signiﬁcance; this conﬁrmed a signiﬁcant reduction in serumInternational Journal of Endocrinology 3
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Figure 1: Change in biochemical parameters pre- and post
commencementofcinacalcet.Thesegraphsdemonstratethechange
in serum calcium and serum PTH pre- and post commencement
of cinacalcet. Each line represents an individual patients’ data. The
grey dotted line indicates the normal reference range.
PTH (P = .018). A signiﬁcant increase was noted in serum
phosphate (P = .012) but no change was found in 24-hour
urinary calcium measurements (Table 2).
Table 2: Biochemical results pre- and post commencement of
cinacalcet with nonparametric statistical analyses.
Premedian
(Range)
Postmedian
(Range)
P-value
Serum Calcium
(mmol/L)
2.76
(2.62–2.91)
2.35
(2.13–2.54)
.012
Serum PTH
(pmol/L)
15.85
(4.8–36.5)
9.7
(2.4–29.4)
.012
Serum Phosphate
(mmol/L)
0.91
(0.77–0.99)
1.04
(0.78–1.31)
.012
Urine Calcium
(mmol/24 hours)
5.02
(2.54–7.79)
3.35
(1.98–5.6)
.144
A comparison was made between pre- and 2 hours post
cinacalcet PTH measurements for the 5 individuals in whom
results were available; no signiﬁcant diﬀerence was detected
(P = .345).
Cinacalcet was well tolerated by six patients; two expe-
rienced gastro-intestinal side eﬀects and one subsequently
discontinued cinacalcet. Duration of treatment was 10–35
months with maintenance of biochemical control achieved
in seven patients; the eighth patient defaulted from clinical
follow up. Incomplete clinical data precluded the statistical
comparison of disease end points; however, no diﬀerence
was noted in BMD for the ﬁve patients reassessed. Patients
with a history of renal calculi had been successfully treated
previously; none demonstrated recurrent stone formation.
5. Discussion
Our data demonstrate that cinacalcet is eﬀective at sig-
niﬁcantly lowering serum calcium and PTH levels but
insuﬃcientdatawereavailabletodrawconclusionsregarding
disease end points. Control of serum calcium and PTH in
MEN1 PHPT patients treated with surgery is associated with
an increase in BMD [2] which suggests that aiming for
biochemical control is an appropriate therapeutic strategy in
these patients. Where surgery is not possible or has failed to
control MEN1 PHPT, cinacalcet does provide an alternative
therapeutic option. Existing medical options are limited;
bisphosphonates are eﬀective in improving bone density but
have no signiﬁcant eﬀect on serum corrected calcium or
PTH levels [9]. Faggiano et al. [10] recently demonstrated
the eﬀectiveness of long acting octreotide in the manage-
ment of MEN1 patients with primary hyperparathyroidism
and duodeno-pancreatic neuroendocrine tumour. However,
long-term adverse metabolic sequelae are likely to outweigh
its beneﬁts for primary hyperparathyroidism alone [11–13].
We have demonstrated a more impressive reduction in
serumPTH(median35.5%,range3.25–67.9%)comparedto
studies of cinacalcet use in sporadic PHPT (mean reduction
7.6%) [6]. Timing of PTH samples in relation to cinacalcet
dosing does account for potential variability in results;
a reduction of 37% has been demonstrated at 2 hours
postdose,withrecoveryofpredoselevelsby8hours[6].Such
pharmacodynamics were not evident in our cohort; no sig-
niﬁcant diﬀerence was detected between predose and 2-hour4 International Journal of Endocrinology
postdose PTH measurements for the ﬁve patients in whom
results were available. All samples within our cohort were
taken predose as per standard clinical practice. The reasons
for the enhanced PTH response seen in our cohort are not
clear; we postulate that the underlying pathology may be of
importance. MEN1 hyperparathyroidism is invariably due to
chief cell hyperplasia rather than a monoclonal adenoma.
It may be possible that the expression of calcium sensing
receptors diﬀers between the two phenotypes and this may
inﬂuence biochemical response to cinacalcet, although data
to support this are currently lacking.
Previously published data highlighted the theoretical
concern of increased urinary calcium excretion with cinacal-
cet use, due to the direct action at the calcium sensing
receptors in the kidney. The overall reduction in serum
calcium appears to counteract this eﬀect and signiﬁcant
changes in urinary calcium excretion have not been demon-
strated in primary hyperparathyroidism [6]. In view of the
theoretical concern, it is the authors’ policy to measure 24-
hour urine calcium levels as part of the patient’s annual
clinical assessment in addition to regular assessment of
serum calcium, phosphate, and PTH measurements.
Eﬀective control of serum calcium and PTH levels in
MEN1PHPTisanappropriatetherapeuticstrategytoreduce
the early onset of associated complications. Where surgery
has been noncurative or is not possible, cinacalcet may
provide a medical alternative; this is supported by our study
and a recent case report of a 30-year-old woman who
maintained biochemical control after 1 year of cinacalcet for
management of MEN1 hyperparathyroidism [14]. Longer-
term prospective studies are needed to further evaluate
clinical eﬀectiveness, safety, and tolerability.
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